Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap Conference

  Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap
  Conference

Bank of America Merrill Lynch Smid Cap Conference 2014

Business Wire

LOS ANGELES -- March 12, 2014

Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical
company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer,
President and Founder of Puma, will present an overview of the Company at
11:45 a.m. EDT on Wednesday, March 19, at the Bank of America Merrill Lynch
2014 Smid Cap Conference. The conference will be held at The Ritz-Carlton,
Boston Common.

A live webcast will be available on the Company’s website at
www.pumabiotechnology.com. The presentation will be archived on the website
and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that
acquires and develops innovative products for the treatment of various forms
of cancer. The Company focuses on in-licensing drug candidates that are
undergoing or have already completed initial clinical testing for the
treatment of cancer and then seeks to further develop those drug candidates
for commercial use. The Company is initially focused on the development of
PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for
the treatment of patients with HER2-positive breast cancer and patients with
non-small cell lung cancer, breast cancer and other solid tumors that have a
HER2 mutation.

Further information about Puma Biotechnology may be found at
www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and
uncertainties that could cause the Company's actual results to differ
materially from the anticipated results and expectations expressed in these
forward-looking statements. These statements are based on current
expectations, forecasts and assumptions, and actual outcomes and results could
differ materially from these statements due to a number of factors, which
include, but are not limited to, the risk factors disclosed in the periodic
reports filed by the Company with the Securities and Exchange Commission from
time to time. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. The
Company assumes no obligation to update these forward-looking statements,
except as required by law.

Contact:

Puma Biotechnology, Inc.
Alan H. Auerbach or Mariann Ohanesian, +1 424-248-6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
or
Russo Partners
Andreas Marathovouniotis or David Schull, +1 212-845-4235
andreas.marathis@russopartnersllc.com
david.schull@russopartnersllc.com
 
Press spacebar to pause and continue. Press esc to stop.